1. Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401) 
Eiji Iwama, MD, PhD, Yasushi Goto, MD, PhD, Haruyasu Murakami, MD, PhD, Taishi Harada, MD, PhD, Shinsuke Tsumura, MD, Hiroyuki Sakashita, MD, PhD, Yoshiaki Mori, MD, PhD, Noriaki Nakagaki, MD, Yuka Fujita, MD, PhD, Masahiro Seike, MD, PhD, Akihiro Bessho, MD, PhD, Manabu Ono, MD, PhD, Akihito Okazaki, MD, Hiroaki Akamatsu, MD, Ryotaro Morinaga, MD, Shinichiro Ushijima, MD, Takayuki Shimose, MMath, Shoji Tokunaga, PhD, Akinobu Hamada, PhD, Nobuyuki Yamamoto, MD, PhD, Yoichi Nakanishi, MD, PhD, Kenji Sugio, MD, PhD, Isamu Okamoto, MD, PhD 
Journal of Thoracic Oncology 
Volume 12, Issue 7, Pages (July 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Waterfall plot of the percentage change in the size of target lesions from baseline to the time of best response. Colors indicate the performance status (PS) of each patient at baseline.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Kaplan-Meier plots of progression-free survival (PFS) for all study patients (A) and for all patients according to history of crizotinib treatment (B) or Eastern Cooperative Oncology Group performance status (PS) at baseline (C). Median PFS (mPFS) values and p values for the difference between two curves as determined with the log-rank test are indicated.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Change in Eastern Cooperative Oncology Group performance status (PS) for each patient from baseline to best status during treatment. The p value for the difference in PS between baseline and best status was determined with the Wilcoxon signed rank test (two sided).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

5. Supplemental Data 1
Change in SpO2 from baseline to best status during treatment for each of 16 patients for whom data were available. *Two points overlap; **four points overlap; ***three points overlap.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions